Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
CURRENT ASSETS    
Cash and cash equivalents $ 55,742 $ 32,585
Marketable equity securities 2,616 8,977
Accounts and grants receivable, net (Note 3) 50,840 4
Prepaid expenses and other current assets 2,351 2,433
Total current assets 111,549 43,999
NONCURRENT ASSETS    
Property and equipment, net (Notes 6 and 14) 4,872 5,630
Deposits and other long-term assets 630 616
Goodwill [1] 10,672 10,672
Intangible assets, net 46,822 47,032
TOTAL ASSETS 174,545 107,949
CURRENT LIABILITIES    
Accounts payable and accrued liabilities 27,969 6,813
Lease liabilities, current portion (Note 14) 801 746
Financing lease, current portion (Note 14) 30 16
Deferred revenues (Note 3) 18,119 193
Liability classified warrants, current portion 197 1
Total current liabilities 47,116 7,769
LONG-TERM LIABILITIES    
Deferred tax liability 2,076 2,076
Deferred revenues, net of current portion (Note 3) 32,454
Lease liability, net of current portion (Note 14) 1,941 2,514
Financing lease, net of current portion 30 26
Liability classified warrants and other long-term liabilities 30 437
TOTAL LIABILITIES 83,647 12,822
SHAREHOLDERS’ EQUITY    
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of December 31, 2021 and 2020, respectively
Common shares, no par value, authorized 250,000 shares; 169,477 and 153,096 shares issued and outstanding as of December 31, 2021 and 2020, respectively 434,529 393,944
Accumulated other comprehensive loss (5,211) (3,667)
Accumulated deficit (337,097) (294,078)
Lineage Cell Therapeutics, Inc. shareholders’ equity 92,221 96,199
Noncontrolling (deficit) (1,323) (1,072)
Total shareholders’ equity 90,898 95,127
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 174,545 $ 107,949
[1] Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger.